We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dynorphin Drives Anxiety

News   May 30, 2018 | Original Story by Chris Palmer for Cold Spring Harbour

 
Neuropeptide of Stress: Dynorphin drives anxiety

Anxiety was traced by the CSHL team to the brain's central amygdala, and to increased excitation of neurons that express the peptide somatostatin (SOM+ neurons). This initial step is demonstrated in these images, by comparing the amount of pink and blue fluorescence in the bottom right frame as compared with the frame directly above it, showing the central amygdala in mice not experiencing anxiety. The full pathway involves additional steps and identifies dynorphin, a signaling molecule, as a possible anti-anxiety drug target.

 
 
 

RELATED ARTICLES

Ultrasmall Electrodes Could Make for Safer Neural Stimulation

News

Neural stimulation has had beneficial therapeutic effects in neurological disorders, such as Parkinson’s disease. While many advancements have been made, implanted devices deteriorate and cause scarring in neural tissue. A new paper details a less invasive method of stimulation that would use an untethered ultrasmall electrode activated by light, a technique that may mitigate damage done by current methods.

READ MORE

Therapy Combo Promising in Small Cell Lung Cancer Model

News

A combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

READ MORE

Open Science Drug Discovery Approach Targets Neurodegenerative Disease

News

Parkinson’s disease and Amyotrophic Lateral Sclerosis, or ALS, are the newest frontiers for open science drug discovery, a global movement led by University of Toronto researchers that puts knowledge sharing and medication affordability ahead of patents and profits.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE